Top Markets
Coin of the day
Yumanity Therapeutics, Inc. Yumanity Therapeutics, Inc.

Yumanity Therapeutics, Inc.

YMTX
株式のランク #28846
Yumanity Therapeutics Inc. operates as a clinical-stage biopharmaceutical... Yumanity Therapeutics Inc. operates as a clinical-stage biopharmaceutical company. Its primary focus lies in the investigation and development of therapeutic solutions for neurodegenerative conditions, particularly those driven by protein misfolding. The firm aims to discover disease-modifying treatments for a range of neurodegenerative disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis (ALS), and frontotemporal lobar degeneration. Central to its pipeline is YTX-7739, an innovative small molecule presently in Phase I clinical trials for Parkinson's disease and associated α-synuclein disorders. Additionally, YTX-9184 is undergoing preclinical studies with the goal of treating diverse neurological conditions. The company maintains a license and research collaboration agreement with Merck Sharp & Dohme Corp. Founded in 2014, Yumanity Therapeutics Inc. is headquartered in Boston, Massachusetts.
株価
$1.89
最終同期: 2022-12-16
時価総額
$24.38M
変化(1日)
8.62%
変化(1年)
0.00%
US
取引 Yumanity Therapeutics, Inc. (YMTX)

カテゴリー

Yumanity Therapeutics, Inc.(YMTX)のEPS
2026 時点のEPS TTM: 0
Yumanity Therapeutics, Inc.の最新の財務報告と株価によると、同社の現在のEPS(TTM)は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
Yumanity Therapeutics, Inc.のEPS履歴(2026から2026まで)
各年末時点のEPS
EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS
企業 EPS EPSの差
$17.32 -
US
$-7.98 -
US
$27.74 -
NL
$2.98 -
AU
- -
CH